Bearded Collie OA BEFORE Stem Cell Therapy

By: MediVet Arizona

Original post:
Bearded Collie OA BEFORE Stem Cell Therapy - Video

2 months after stem cell therapy
Eveybody agrees that the therapy works. There is very big improvment the way Toby walks now.

By: Jacek Kozlowski

More here:
2 months after stem cell therapy - Video

By: Jet Villa, InterAksyon.com August 20, 2013 3:45 PM

InterAksyon.com The online news portal of TV5

MANILA, Philippines Reminder for those who wish to have their stem cell therapy practice and products accredited: You have until August 31 to register, the Department of Health said Tuesday.

Citing Administrative Order 2013-0012 issued March 18 this year, Health Secretary Enrique Ona said that while the Department of Health (DOH) supports scientific advancement in the field of cellular medicine, its priority is to protect the public from harm rather than give a blanket endorsement of its use or potential benefits.

Those who need to seek accreditation include: health care facilities doing stem cell therapy (with the DOH) as well as companies that import, market, and produce stem cell products (with the Food and Drug Administration, which is under DOH).

Ona said the DOH seeks to regulate stem cell therapy both as a recognized treatment modality and for research purposes.

"This is to allay fears that unscrupulous individuals or groups will engage in unethical practices and subject naive patients to undue harm and unproven medical claims," he added.

Among the DOH guidelines are:

Ona conceded that there are only a limited number of medical conditions in which stem cell therapy may be indicated.

Others are claims that should be taken with a grain of salt, he said.

The rest is here:
REMINDER | Stem-cell therapy accreditation deadline is Aug. 31 - DOH

By Philip C. Tubeza Philippine Daily Inquirer

MANILA, PhilippinesSaying that doctors were exacting exorbitant fees for what is still experimental medicine, the Philippine College of Physicians (PCP) launched Tuesday an online petition urging the Department of Health (DOH) to put a stop to experimental stem cell therapies in the country.

Human stem cell therapy for unproven indications is proliferating in the Philippines and posing serious safety issues to unknowing Filipinos The Philippine College of Physicians is alarmed by the false claims, misinformation and exorbitant fees for such stem cell treatments, read the petition on http://www.change.org.

The PCP urged the DOH to issue a cease and desist order to all doctors performing such therapies as the Philippine Health Insurance Corp. (PhilHealth) clarified that stem cell therapy was not covered by the governments universal healthcare program.

Cease and desist

We, the undersigned, call on the (DOH) to issue a cease and desist order to all doctors, clinics and hospitals that [offer] human stem cell therapy for unproven indications until scientific evidence to support claims of efficacy and safety are approved by the Food and Drug Administration, it said.

The PCP, the umbrella organization of Internal Medicine specialists in the country, said that transplanting human blood-forming stem cells to treat cancerous and noncancerous diseases of the blood was the most widely accepted clinical application of stem cell therapy.

The effectiveness and safety of human stem cell therapy has yet to be proven for heart, neurologic, skin, rheumatologic and gastrointestinal diseases, diabetes, hypertension, autism, cancer, aging and aesthetics, HIV/AIDS and other conditions, the group said.

Lack of evidence

Despite the lack of solid scientific evidence to support the [application] of human stem cell therapy for these conditions, reports of its use precisely for these conditions being received and exorbitant fees being paid by prominent personalities abound in media, the PCP said.

The rest is here:
Docs seek stop to expensive, experimental stem cell therapy

CHEYENNE, WY- (ACCESSWIRE - August 20,2013) - Therapy Cells Inc (OTC Pink: TCEL) announces that on 13 February 2013, US patent US 11/702,895 was awarded to renowned scientist Dr Patrick Casey and Transplantation Ltd, for his transformational cell therapy, exclusively licensed to Therapy Cells Inc for use in human applications.

This revolutionary science dispenses with the traditional notion that cells cannot divide once they are fully mature. Dr Casey has shown that adult cells, given the right environment, can in fact divide and be grown in the laboratory. These new cells can then be used for transportation back to damaged tissue in the body, to enact tissue and organ healing.

The research team headed by Dr Casey has to date treated more than 80 horses including thoroughbreds, standardbreds, polo ponies and horses at the highest level of equestrian competition.

"With a growing level of trial success in horses, Therapy Cells' target is to gain FDA approval, and in short order have human applications in human tendons," Dr Casey says. "An initial valuation of $30 million USD for our science and technology has been appraised. FDA approval for clinical use of this technology in humans, will likely increase this factor by at least 10 times." The horse is an FDA approved model species for athletic injuries.

Dr Casey is a Veterinary graduate from Massey University (BVSc, 1988), and graduate from the University of California in 1992 with a Doctor of Philosophy (PhD, Comparative Pathology). During his time in the United States he also completed an Equine Surgical Internship at Hagyard-Davidson and McGee, Lexington, Kentucky, followed by a three year residency programme in Equine Reproduction, with a minor in Equine Medicine at UC Davis. In 1992, 1993, and 1994 he received a post-doctoral fellowship from the Equine Research Laboratory at the University of California, which allowed him to set up with the late, world renowned, Professor Liggins at the University of Auckland, New Zealand.

Since 2011, Dr Casey has been chief scientific consultant to a public company in the USA - Therapy Cells Inc (TCEL on the OTC Market).

This exciting Bio Tech/Med tech Company holds the exclusive technology that allows adult cells from a specific tissue (e.g. Achilles tendon) to grow again from an individual to enact repair and regeneration of that tissue, effectively by-passing the need for Stem Cell treatment.

"The financial and curative potential of this biotechnology platform is immediately obvious," states Dr Casey. "When we talk about regenerative procedures, the ability to rejuvenate tissues and organs with cultivated natural cell therapy, it's easy to understand how enormous the opportunity and the impact will be. The awarding of this US Patent for our transformational science is a significant milestone in the steps we have been taking to get our therapies to market."

Contact:

Contact: Patrick Casey

See the article here:
Therapy Cells, Inc Receives USA Patent Granted for Revolutionary Cell Therapy

ALAMEDA, Calif.--(BUSINESS WIRE)--

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, announced that Chief Executive Officer Michael D. West, PhD will give the keynote address at the MSC 2013 Adult Stem Cell Therapy & Regenerative Medicine conference on Monday, August 19, 2013, at 12:15 p.m. EDT in Cleveland, Ohio. Dr. West will discuss the potential use of embryonic mesenchymal progenitor cells, generated using BioTimes PureStemtechnology, in regenerative medicine and will contrast the properties of those cells with adult-derived mesenchymal stem cells. He will also discuss how those cells can be utilized in the search for genes potentially useful in induced tissue regeneration (iTR). The presentation will be available on BioTimes website at http://www.biotimeinc.com/scientific-presentations.

MSC 2013 Adult Stem Cell Therapy & Regenerative Medicine, August 19-21, 2013, is being held at the Cleveland Marriott Downtown at Key Center and is presented by Case Western Reserve University and the National Center for Regenerative Medicine.

About BioTime, Inc

BioTime is a biotechnology company engaged in research and product development in the field of regenerative medicine. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. BioTimes focus is on pluripotent stem cell technology based on human embryonic stem (hES) cells and induced pluripotent stem (iPS) cells. hES and iPS cells provide a means of manufacturing every cell type in the human body and therefore show considerable promise for the development of a number of new therapeutic products. BioTimes therapeutic and research products include a wide array of proprietary PureStem progenitors, HyStem hydrogels, culture media, and differentiation kits. BioTime is developing Renevia (a HyStem product) as a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. In addition, BioTime has developed Hextend, a blood plasma volume expander for use in surgery, emergency trauma treatment and other applications. Hextend is manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive licensing agreements.

BioTime is also developing stem cell and other products for research, therapeutic, and diagnostic use through its subsidiaries:

Additional information about BioTime can be found on the web at http://www.biotimeinc.com.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime's Securities and Exchange Commission filings. BioTime disclaims any intent or obligation to update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://news.biotimeinc.com.

Read the original post:
BioTime CEO Dr. Michael West to Give Keynote Address at the MSC 2013 Adult Stem Cell Therapy & Regenerative Medicine ...

What #39;s Stem Cell Therapy Dr Bill Johnson Has Answers
for more information go to... http://www.innovationstemcellcenter.com More useful info below... Drapeau #39;s theory that Adult Stem Cells are nothing less than the hum...

By: Mark Khan

Excerpt from:
What's Stem Cell Therapy Dr Bill Johnson Has Answers - Video

Stem Cell Therapy: Where #39;s the Evidence?
Dr. Tony Dans of the University of the Philippines College of Medicine discusses dilemmas in research and regulation of stem cell therapy in the Philippines....

By: Antonio Dans

See original here:
Stem Cell Therapy: Where's the Evidence? - Video

By: Jet Villa, InterAksyon.com August 18, 2013 5:02 PM

REUTERS FILE PHOTO

InterAksyon.com The online news portal of TV5

MANILA, Philippines - The Food and Drug Administration (FDA) will conduct on Friday, August 23, a public hearing on the regulation of stem cell therapy in the country.

The FDA said the public hearing is scheduled from 3 p.m. to 5 p,m, at the Audio-Visual Room, 3rd floor, Annex Building, FDA office on Civil Drive in Alabang Muntinlupa.

The purpose of the hearing is to discuss the regulation of stem cell therapy, the stem cell products, and the health facilities that are offering the service in the court, it said.

The FDA also established an online reporting system to document adverse events linked to human cells, tissues, and cellular- and tissue-based products such stem cell therapies acquired in any facility.

The agency said those who experienced any untoward event or side effect or treatment failures after undergoing stem cell procedures can report through FDA website at http://www.fda.gov.ph under eReport and Adverse Drug Reaction, Report section.

E-mails may also be sent toreport@fda.gov.ph.

All consumers are assuredthat all information given will be treated with utmost confidentiality.Contact details are needed in case of a need for follow-up and validation.However, anonymous reports will still be accepted, the FDA added.

Read more:
FDA hearing on stem cell therapy set on Friday, Aug. 23

Genetic Engineering Produces A Genuine Monstrosity Forbes Activists have warned for decades that genetic engineering would create some sort of monstrosity like Dr. Frankenstein's creature. It turns out they were right: Government regulation has run amok and threatens advances in agriculture. USDA's existing ... and more »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNGWS16v9GdK_UBwyHS6r9K3l8Hrug&url=http://www.forbes.com/sites/henrymiller/2013/08/14/activists-vindicated-genetic-engineering-produces-a-genuine-monstrosity/

ABC News

Genetic engineering project begins with glow-in-the-dark rabbits, but it could ... MedCity News The point of the flashy genetic engineering is not to give pet store owners a new product to hawk, but rather to confirm that the techniques researchers use to transfer genes into a genome are working. And in many cases, the greater goal is to develop ... UNIVERSITY OF HAWAII AT MANOAStuff.co.nz A Gene That Was Not Originally in Animals Now ExistsFrench Tribune all 86 news articles »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNEPiBC6FZKjHTWNSF0GTf4icyVt-Q&url=http://medcitynews.com/2013/08/genetic-engineering-project-begins-with-glow-in-the-dark-rabbits-but-it-could-lead-to-better-disease-treatment/

Ghana Business News

Ghana to tap into genetic engineering – Biochemist Ghana Business News Dr Yaa Difie Osei, a biochemist and molecular biologist, has said the country was positioning itself to tap into the benefits of modern biotechnology and genetic engineering for guaranteed food security. She said structures including institutional and ... and more »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNHK5wXMzsXLKNC24BWmDpGV2QQ8BQ&url=http://www.ghanabusinessnews.com/2013/08/16/ghana-to-tap-into-genetic-engineering-biochemist/

Melanoma combination therapies ward off tumor resistance Nature.com Nature Biotechnology. Access provided to Google by Bot. Cart · Home · Advance online publication · Current issue · Archive · Focuses and Supplements · Press releases. Search Go Advanced search · nature.com · journal home · current issue · News; full text.

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNEC6K297RNDDEcExxVQoL_cIG_oRg&url=http://www.nature.com/nbt/journal/v31/n8/full/nbt0813-666b.html

MorphoSys Biotechnology Success Offers European Blueprint Bloomberg Biotechnology companies have struggled for financing in Europe, and the region has failed to produce companies the size of Amgen Inc. (AMGN) or Gilead Sciences Inc. (GILD) of the U.S., which have market values of more than $80 billion. To surmount ... and more »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNHBs3fpvw--FURrYpn73C2Sue4pXA&url=http://www.bloomberg.com/news/2013-08-12/morphosys-biotechnology-success-offers-european-blueprint.html

Huntsville biotechnology company Kailos Genetics approved to test human DNA ... The Huntsville Times - al.com HUNTSVILLE, Alabama – Huntsville biotechnology company Kailos Genetics is expanding its capabilities in the emerging science of personal medicine in a move to grow both the company and Huntsville's biotechnology sector. “All of the underpinnings are ...

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNEHU9aNSTkd5dzWCba3nlDKkKFNog&url=http://www.al.com/business/index.ssf/2013/08/huntsville_biotechnology_compa.html

Extent of Genetic Overlap in Key Mental Disorders Revealed Medscape "These results give us by far the clearest picture available to date of the degree of genetic similarity between these key psychiatric disorders," co–senior author Kenneth S. Kendler, MD, professor of psychiatry and human and molecular genetics in the ... and more »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNEeg4Jm9_nJ3iUsb_Vslk_0iY_upg&url=http://www.medscape.com/viewarticle/809587

Earlier this year Yaniv Erlich of the Whitehead Institute for Biomedical Research at M.I.T. sent bioethicists into a frenzy when he and his team uncovered the names of people whose anonymous genome...

-- Read more on ScientificAmerican.com

Source:
http://rss.sciam.com/~r/sciam/topic/gene-therapy/~3/c3dvzwuFAUI/article.cfm

“Jerry Brown's
veto of AB926
which would allow young women to be paid for multiple egg extractions
for scientific research is one for the gals.  In western Ireland
women secreted away their 'butter
and eggs'
money in anticipation of hard times. In my day every smart girl had
her 'mad money' to escape a bad situation. Secret cash for young
women is a great idea, but not when it turns on multiple cycles of
pumping powerful hormones associated (in other contexts) with ovarian
cancer into young women's bodies to produce 30 or 60 eggs a month.
That's not promoting gender equity no matter what some of our best
Democratic women leaders have to say. Selling sperm and selling eggs
are a totally different matter. One  is pleasurable and safe,
the other is a complicated and invasive procedure. We need good
science and good research and  freedom of choice and action. We
also need protection from false advertising. There are no
evidence based, long term studies of the effects of these hormone
injections on women ten or twenty years after the fact. Let's fund
those needed longitudinal and cohort studies and hope for the best.
In the meantime, women had best stick to 'butter and eggs' money. It
doesn't pay a lot, but it's less painful and a heck of a lot safer.”

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/gMworjXp5x0/butter-and-eggs-money-and-gubernatorial.html

Susan Bonilla Photo from California Legislature

“Not everything in life is for sale
nor should it be.”

“It (the governor's veto) shows a
glaring inconsistency...The veto statement was very overreaching in
the fact that it was making very broad statements about what women
should be able to do, and while it's not legislation it certainly
goes to a mindset that the governor has that I find particularly
troubling.”

“Market-driven compensation of donors
by donor agencies and prospective parents continues unchecked.”

“Many women...will be denied hope and
the possibility of giving birth to a child because research on their
behalf has been halted in California.”

“It would be unconscionable to
expand the commercial market in women’s eggs without obtaining
significantly more information about the risks of retrieving them.” 

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/j0Fm9p1Ac64/bonilla-veto-of-pay-for-eggs-bill-shows.html

“Not everything in life is for sale
nor should it be.”

"Not everything in life is for sale
nor should it be.

"This bill would legalize the payment of
money in exchange for a woman submitting to invasive procedures to
stimulate, extract and harvest her eggs for scientific research.

"The questions raised here are not
simple; they touch matters that are both personal and philosophical.

"In medical procedures of this kind,
genuinely informed consent is difficult because the long-term risks
are not adequately known. Putting thousands of dollars on the table
only compounds the problem.

"Six years ago the Legislature, by
near unanimity, enacted the prohibition that this bill now seeks to
reverse. After careful review of the materials which both supporters
and opponents submitted, I do not find sufficient reason to change
course.

"I am returning this bill without my
signature."

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/1eDn2Is8V8E/california-gov-jerry-brown-vetoes-pay.html